Biosimilars Market Access in Psoriasis 2017: TNF-alpha inhibitors Enbrel, Humira, and Remicade have Long Held … – GlobeNewswire (press release)

May 30, 2017 05:15 ET | Source: Research and Markets

Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

2. Five Major EU Markets

3. Methodology

For more information about this report visit http://www.researchandmarkets.com/research/7tcv43/biosimilars

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Go here to read the rest:
Biosimilars Market Access in Psoriasis 2017: TNF-alpha inhibitors Enbrel, Humira, and Remicade have Long Held ... - GlobeNewswire (press release)